Overview

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Status:
RECRUITING

Trial end date:
2026-05-15

Target enrollment:

Participant gender:

Summary

This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer.

Phase:

PHASE1

Details

Lead Sponsor:

Boryung Pharmaceutical Co., Ltd

Treatments:

olaparib